Rivas Medical Weight Loss

Rivas Medical Weight Loss operates in Annapolis, Maryland, delivering physician-supervised weight management programs that integrate GLP-1 receptor agonist peptides with metabolic diagnostics and structured nutritional guidance. Dr. Rivas leads the practice with a protocol-driven approach that begins with comprehensive laboratory panels and body composition analysis using bioelectrical impedance or DEXA scanning to establish baseline metabolic function before initiating any pharmacological intervention. The clinic serves patients throughout Maryland, Virginia, and Florida through both in-person consultations at the Annapolis location and HIPAA-compliant telehealth appointments for ongoing management and medication adjustments.

The peptide therapy program centers on two FDA-approved GLP-1 medications: semaglutide, administered as a once-weekly subcutaneous injection starting at 0.25 mg with gradual titration to therapeutic doses, and tirzepatide, a dual GIP/GLP-1 receptor agonist that targets both incretin pathways for enhanced glycemic control and appetite regulation. Dr. Rivas determines peptide selection based on individual metabolic profiles, insulin resistance markers including fasting insulin and HOMA-IR scores, and patient-specific factors such as cardiovascular risk profiles and gastrointestinal tolerance. Each medication protocol includes detailed injection training, proper refrigeration storage instructions, and monitoring schedules for potential side effects including nausea, constipation, or changes in heart rate that require dose modification.

Dr. Rivas structures weight management programs around quarterly metabolic reassessments that track changes in fasting glucose, hemoglobin A1c, lipid panels, liver enzymes, and thyroid function to ensure peptide therapy produces beneficial metabolic shifts beyond scale weight reduction. Nutritional counseling sessions address macronutrient distribution tailored to each patient's activity level and metabolic type, with specific guidance on protein intake targets between 0.8-1.2 grams per kilogram of ideal body weight to preserve lean muscle mass during caloric restriction. The clinic provides patients with food logging systems and reviews dietary records during follow-up visits to identify patterns that may impede progress or contribute to peptide side effects, particularly the timing of meals relative to injection schedules.

Patients initiating treatment at Rivas Medical Weight Loss undergo an initial consultation that includes medical history review with attention to contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, current medication reconciliation to identify potential drug interactions, and discussion of realistic weight loss expectations based on clinical trial data showing average reductions of 15-20% of body weight over 68 weeks with tirzepatide at maximum doses. Follow-up appointments occur every 4-6 weeks during the titration phase to assess tolerance and efficacy, then transition to monthly or quarterly visits once patients reach maintenance dosing. The practice maintains a 5.0-star rating across 15 Google reviews, reflecting patient feedback on the thoroughness of Dr. Rivas's evaluation process and the accessibility of the care team for questions about injection technique or managing side effects between scheduled appointments.

The telehealth platform extends access to patients across Maryland, Virginia, and Florida who cannot travel regularly to Annapolis, with virtual visits conducted via secure video conferencing that allows Dr. Rivas to review lab results, assess progress photos and weight logs, and adjust peptide dosing remotely. Prescriptions are transmitted electronically to patients' preferred pharmacies, including compounding facilities for customized formulations when commercially available products are unsuitable due to dosing requirements or cost considerations. The clinic coordinates with local laboratories in each state to ensure patients can complete required monitoring bloodwork without traveling to Maryland, maintaining continuity of care regardless of geographic location while adhering to each state's telemedicine regulations and prescribing requirements for controlled metabolic medications.